G Linazasoro

Summary

Affiliation: Hospital Universitario
Country: Spain

Publications

  1. ncbi Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions
    Gurutz Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Guipuzcoa, Spain
    Mov Disord 19:743-54. 2004
  2. ncbi Cell therapy for Parkinson's disease: only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson's disease
    Gurutz Linazasoro
    Centro de Investigación Parkinson CIP, Policlinica Gipuzkoa, San Sebastiáin, Spain
    Cell Transplant 15:463-73. 2006
  3. ncbi Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial
    Gurutz Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, Parque Tecnológico de Miramón, San Sebastian, Spain
    Arch Neurol 64:137-40. 2007
  4. ncbi Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats
    Laura Grandoso
    Departamento de Farmacologia, Universidad del Pais Vasco, E 48940 Leioa, Vizcaya, Spain
    Int J Pharm 343:69-78. 2007
  5. doi A global view of Parkinson's disease pathogenesis: implications for natural history and neuroprotection
    G Linazasoro
    Centro de Investigacion Parkinson, Fundación Dr Carlos Elósegui, Policlinica Gipuzkoa, Parque Tecnológico Miramón, 174, 20009 San Sebastian, Gipuzkoa, Spain
    Parkinsonism Relat Disord 15:401-5. 2009
  6. doi Should levodopa dose be reduced when switched to stalevo?
    G Linazasoro
    Centro Investigación Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    Eur J Neurol 15:257-61. 2008
  7. ncbi Classical Parkinson disease versus Parkinson complex--reflections against staging and in favour of heterogeneity
    G Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, Parque Tecnológico Miramón, San Sebastián Guipúzcoa, Spain
    Eur J Neurol 14:721-8. 2007
  8. ncbi Prevalence of tic disorder in two schools in the Basque country: Results and methodological caveats
    Gurutz Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    Mov Disord 21:2106-9. 2006
  9. ncbi Severe stuttering and motor tics responsive to cocaine
    G Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, Parque Tecnológico de Miramón, San Sebastian, Gipuzkoa, Spain
    Parkinsonism Relat Disord 13:57-8. 2007
  10. ncbi Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study
    Gurutz Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    Clin Neuropharmacol 28:176-8. 2005

Collaborators

Detail Information

Publications49

  1. ncbi Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions
    Gurutz Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Guipuzcoa, Spain
    Mov Disord 19:743-54. 2004
    ..Some of the recent trials and possible reasons for their lack of success are critically analysed. Finally, some suggestions to avoid further failures and improve results are proposed...
  2. ncbi Cell therapy for Parkinson's disease: only young onset patients allowed? Reflections about the results of recent clinical trials with cell therapy and the progression of Parkinson's disease
    Gurutz Linazasoro
    Centro de Investigación Parkinson CIP, Policlinica Gipuzkoa, San Sebastiáin, Spain
    Cell Transplant 15:463-73. 2006
    ..On the other hand, this can also explain the appearance of unexpected side effects such as the "runaway" dyskinesias reported following transplantation...
  3. ncbi Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial
    Gurutz Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, Parque Tecnológico de Miramón, San Sebastian, Spain
    Arch Neurol 64:137-40. 2007
  4. ncbi Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats
    Laura Grandoso
    Departamento de Farmacologia, Universidad del Pais Vasco, E 48940 Leioa, Vizcaya, Spain
    Int J Pharm 343:69-78. 2007
    ..In summary, the implantation of microencapsulated GDNF secreting cells allows the delivery of this molecule into the rat striatum for at least 6 months and results in substantial behavioral improvement...
  5. doi A global view of Parkinson's disease pathogenesis: implications for natural history and neuroprotection
    G Linazasoro
    Centro de Investigacion Parkinson, Fundación Dr Carlos Elósegui, Policlinica Gipuzkoa, Parque Tecnológico Miramón, 174, 20009 San Sebastian, Gipuzkoa, Spain
    Parkinsonism Relat Disord 15:401-5. 2009
    ..The concept of neuroprotection should be modified, shifting the focus from neurons that are lost to those that survive...
  6. doi Should levodopa dose be reduced when switched to stalevo?
    G Linazasoro
    Centro Investigación Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    Eur J Neurol 15:257-61. 2008
    ....
  7. ncbi Classical Parkinson disease versus Parkinson complex--reflections against staging and in favour of heterogeneity
    G Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, Parque Tecnológico Miramón, San Sebastián Guipúzcoa, Spain
    Eur J Neurol 14:721-8. 2007
    ..In contrast, the notion of classical and clinically significant PD can explain many of the well-characterized pathological and clinical features of the disease and it gives support to the idea that the magic word in PD is variability...
  8. ncbi Prevalence of tic disorder in two schools in the Basque country: Results and methodological caveats
    Gurutz Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    Mov Disord 21:2106-9. 2006
    ..Most of identified cases were quite mild, not leading to major functional disability. In spite of the methodology employed, it is possible that some cases were lost...
  9. ncbi Severe stuttering and motor tics responsive to cocaine
    G Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, Parque Tecnológico de Miramón, San Sebastian, Gipuzkoa, Spain
    Parkinsonism Relat Disord 13:57-8. 2007
    ..We report on a patient with severe stuttering and mild facial tics which were dramatically improved by cocaine, challenging previous reports...
  10. ncbi Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study
    Gurutz Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    Clin Neuropharmacol 28:176-8. 2005
    ..Only 1 out of 10 patients experienced transient and mild gastrointestinal side effects. This study suggests that donepezil may be useful in the treatment of the dysexecutive syndrome associated with PD...
  11. ncbi New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity
    Gurutz Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    Trends Pharmacol Sci 26:391-7. 2005
    ..Treatment decisions are likely to rely on this information, challenging the relevance of current 'hot' debates about how to start treatment in PD...
  12. ncbi [Onset of dopaminergic therapy in Parkinson's disease: six good reasons not to delay it]
    G Linazasoro
    Unidad de Neurología y Neurocirugía Funcional, Clinica Quiron, San Sebastian, Centro de Investigacion Parkinson, Policlínica Guipuzkoa, Spain
    Neurologia 23:299-305. 2008
    ..In addition, there are other experimental and clinical data that support this idea. On the other side of the argument is the possibility that early use of drugs may inducing adverse effects in non-disabled patients...
  13. doi Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?
    G Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    J Neural Transm 115:431-41. 2008
    ..More importantly, observed discrepancies between the results in models and patients, could challenge the validity of current ideas about the pathophysiology of parkinsonism and LID...
  14. ncbi [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology]
    G Linazasoro
    Centro de Investigacion Parkinson, Policlínica Guipuzkoa, San Sebastian
    Neurologia 24:113-24. 2009
    ..Therefore, it is urgent to develop therapies able to positively modify this outcome. Despite neuroprotection is a research priority in PD, no effective strategies have been found so far...
  15. doi Dopamine dysregulation syndrome and levodopa-induced dyskinesias in Parkinson disease: common consequences of anomalous forms of neural plasticity
    Gurutz Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, San Sebastian, Spain
    Clin Neuropharmacol 32:22-7. 2009
    ..By contrast, molecular data suggest that functional segregation may be lost in addiction, DDS, and dyskinesias. The existence of common pathogenic mechanisms for both phenomena could provide the basis for common therapeutic strategies...
  16. doi Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A
    Terrence Hunt
    Department of Biological Sciences, Allergan, Inc, Irvine, CA, USA
    Clin Neuropharmacol 32:28-31. 2009
    ..To assess the potency of a formulated drug product containing 150-kd botulinum toxin type A (BoNT/A) as the active pharmaceutical ingredient...
  17. ncbi [If I were to wake up clumsy and shaking (10 years later)]
    G Linazasoro
    Centro de Investigacion Parkinson, Policlinica Guipuzcoa, Parque Tecnológico de Miramón, San Sebastian
    Neurologia 23:449-55. 2008
    ..Several studies support the recommendation of not delaying the onset of dopaminergic therapies. Nonetheless, neuroprotection still has not been totally demonstrated and this continues to be an objective of priority...
  18. doi Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study
    Gurutz Linazasoro
    Centro Investigación Parkinson, Fundación Dr Carlos Elósegi, Policlinica Gipuzkoa, Parque Tecnológico de Miramón 174, San Sebastian, Spain
    Clin Neuropharmacol 32:326-9. 2009
    ..Factors related to sex and body weight could play an important role. However, these findings should be considered cautiously because of the limited statistical power of the study...
  19. doi Potential applications of nanotechnologies to Parkinson's disease therapy
    G Linazasoro
    Centro de Investigacion Parkinson, Policlinica Gipuzkoa, Parque Tecnológico de Miramón, 174, 20009 San Sebastián Guipúzcoa, Spain
    Parkinsonism Relat Disord 14:383-92. 2008
    ..All of them are relevant to improve current therapy of Parkinson's disease (PD)...
  20. ncbi [Rasagiline in Parkinson's disease]
    G Linazasoro
    Centro de Investigacion Parkinson, Policlínica Guipuzkoa, San Sebastian, Spain
    Neurologia 23:238-45. 2008
    ..Results of the ADAGIO study are awaited with interest. Therefore, rasagiline is especially well suited as to be used as the initial treatment of PD...
  21. doi Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease
    Gurutz Linazasoro
    Centro de Investigación Parkinson Policlínica Gipuzkoa, San Sebastian, Spain
    Clin Neuropharmacol 31:19-24. 2008
    ..This pharmacological profile may result in clinically different effects. Small clinical trials indicate that overnight switching from 1 agonist to another can be performed safely...
  22. ncbi Etiological and therapeutical observations in a case of belly dancer's dyskinesia
    Girutz Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clínica Quirón Donostia, San Sebastian, Gipuzokoa, Spain
    Mov Disord 20:251-3. 2005
    ..This case presented two peculiarities: (1) the condition was induced by the chronic use of clebopride, and (2) abdominal dyskinesias showed a dramatic response to the application of transcutaneous electrical nerve stimulation...
  23. ncbi Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease
    Gurutz Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Spain
    Neurology 63:589-90. 2004
  24. ncbi [Stem cells: solution to the problem of transplants in Parkinson's disease?]
    G Linazasoro
    Centro de Neurologia y Neurocirugia Funcional Clinica Quirón, San Sebstián, Espana
    Neurologia 18:74-100. 2003
    ..Finally, ethical controversies should be carefully managed. Neurología 2003;18(2):74-100..
  25. ncbi Possible sporadic rapid-onset dystonia-parkinsonism
    Gurutz Linazasoro
    Centro de Neurologia y Neurocirugia, Clinica Quiron, San Sebastian, Spain
    Mov Disord 17:608-9. 2002
    ..We describe the case of a woman with a clinical picture highly suggestive of rapid onset dystonia-parkinsonism (RDP) and no family history of the disease...
  26. ncbi [Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa]
    G Linazaroso
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian
    Neurologia 19:117-27. 2004
    ..Thus, this may have important implications for the discovery of new therapeutic strategies...
  27. ncbi Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease
    G Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, Parque Alcolea s n, 20012 San Sebastian, Guipuzcoa, Spain
    J Neurol 251:335-9. 2004
    ..Objective To determine safety and efficacy of overnight switching from dopamine agonists to pramipexole in patients with advanced Parkinson's disease (PD)...
  28. ncbi PET studies and physiopathology of motor fluctuations in Parkinson's disease
    G Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Spain
    Brain 127:E15; author reply E16. 2004
  29. ncbi Pharmacological and PET studies in patient's with Parkinson's disease and a short duration-motor response: implications in the pathophysiology of motor complications
    G Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Spain
    J Neural Transm 111:497-509. 2004
    ..05) and a trend towards significance (positive correlation) with RACLO uptake was observed (p:0.07). These results suggest that both pre and postsynaptic mechanisms are involved in the origin of the SDR...
  30. ncbi [Pathophysiological bases, clinical results and indications for surgical treatment in Parkinson disease]
    J A Obeso
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian
    Neurologia 14:54-71. 1999
    ..However, much work remains to be done in order to understand several aspects not clearly elucidated at present. The results and current indications for pallidotomy and deep brain stimulation are analyzed...
  31. ncbi [Pallidotomy in the treatment of complicated Parkinson's disease: clinical results at two years and analysis of prognostic factors]
    G Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian
    Neurologia 14:53-61. 1999
    ..There is a renewed interest in pallidotomy as a treatment for complicated Parkinson's disease (PD)...
  32. ncbi [Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]]
    G Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, Parque Alcolea, s n 20012 San Sebastián, Guipuzcoa
    Neurologia 16:17-29. 2001
    ..The most important paradox is the disappearance of levodopa-induced dyskinesias after pallidal surgery. This review critically analyzes the validity of the current model based on the surgical observations...
  33. ncbi Effects of gabapentin on the motor response to levodopa: a double-blind, placebo-controlled, crossover study in patients with complicated Parkinson disease
    N van Blercom
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Spain
    Clin Neuropharmacol 27:124-8. 2004
    ..Gabapentin is an antiepileptic drug that increases the synthesis and release of GABA. Previous studies suggest that gabapentin may be useful in Parkinson disease (PD)...
  34. ncbi [Treatment of Parkinson disease: therapeutic reserve of the dopaminergic agonist]
    G Linazasoro
    Unidad de Neurología y Neurocirugía Funcional, Clinica Quiron, San Sebastian, Centro de Investigacion Parkinson, Policlínica Guipuzkoa
    Neurologia 21:365-75. 2006
    ..The first effective dose, defined as an improvement superior to 30 % is observed with 9 mg/day in 75 % of the patients while the maximum recommended dose is 24 mg/day. This threshold is less with other dopamine agonists...
  35. ncbi Closed doors and false expectations: cell-based therapies for PD
    Gurutz Linazasoro
    Centro de Neurología y Neurocirurgía functional, Clínica Quirón Donostia
    Lancet Neurol 3:454-5. 2004
  36. ncbi Unilateral subthalamic deep brain stimulation in advanced Parkinson's disease
    Gurutz Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Guipuzcoa, Spain
    Mov Disord 18:713-6. 2003
    ..Dyskinesias were ameliorated. Levodopa daily dose was reduced. Three patients required the implantation of the second electrode. Unilateral DBS may be efficacious in some patients with advanced PD...
  37. ncbi Myopathic camptocormia in a patient with levodopa unresponsive parkinsonism
    G Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Spain
    Neurologia 17:162-4. 2002
    ..However, several cases of parkinsonism and dropped head due to neck extensor myopathy have been reported. We report the first patient with levodopa unresponsive parkinsonism and camptocormia of muscular origin...
  38. ncbi [Surgery of the subthalamic nucleus in Parkinson's disease]
    G Linazasoro
    Centro de Neurologia y Neurocirugia Funcional, Clinica Quiron, San Sebastian, Guipuzcoa, Espana
    Rev Neurol 30:1066-72. 2000
    ..The long term efficacy is being studied and preliminary data indicate that the clinical benefit obtained is maintained in the long term...
  39. ncbi [Spinal cord compression due to a epidural lipoma]
    E Urculo
    Servicios de Neurocirugía, Policlinica Gipuzkoa, San Sebastian
    Neurocirugia (Astur) 19:156-60. 2008
    ..Histopathologically the tumour consists of a mature adipose cells matrix intermixed with vascular endothelial channels, that is the reason why it is also named angiolipomas...
  40. ncbi Malignant syndrome in Parkinson's disease
    Gurutz Linazasoro
    Parkinsonism Relat Disord 10:115-6. 2003
  41. ncbi Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment
    Gaizka Bilbao
    Department of Neurosurgery, Cruces Hospital E 48903, Bizkaia, Spain
    Brain Res 1084:175-84. 2006
    ..In this model, subthalamotomy does not modify the firing pattern while levodopa treatment efficiently restores normal firing of SNpc neurons and does not appear to be toxic to them...
  42. ncbi Impact of fatigue in Parkinson's disease: the Fatigue Impact Scale for Daily Use (D-FIS)
    Pablo Martinez-Martin
    Unit of Neuroepidemiology, National Centre for Epidemiology, ISCIII, Madrid, The Spanish Network HOHSR, Spain
    Qual Life Res 15:597-606. 2006
    ..In PD, D-FIS is a consistent and valid measure for fatigue, a frequent symptom previously found to impair patients' HRQoL. Fatigue was also linked to depression and disability in this study...
  43. ncbi Levodopa-induced ocular dyskinesias in Parkinson's disease
    Gurutz Linazasoro
    Centro de Neurología y Neurocirugía funcional Clínica Quirón San Sebastián, Spain
    Mov Disord 17:186-7. 2002
    ....
  44. ncbi Olfaction testing in PD: risky conclusions
    Gurutz Linazasoro
    Mov Disord 23:1060. 2008
  45. ncbi [Investigation in stem cells]
    Gurutz Linazasoro
    Med Clin (Barc) 123:93-4. 2004
  46. ncbi The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene
    Allison Brashear
    Department of Neurology, Wake Forest University, Winston Salem, NC 27157, USA
    Brain 130:828-35. 2007
    ..A positive family history is not required. Genetic testing for the ATP1A3 gene is recommended when abrupt onset, rostrocaudal gradient and prominent bulbar findings are present...
  47. ncbi Grafts in parkinsonism
    Gurutz Linazasoro
    J Neurosurg 97:1250-1; author reply 1251. 2002
  48. ncbi Transcultural comparison of psychogenic movement disorders
    Esther Cubo
    Sanatorio del Rosario, Clinica de la Zarzuela, Neurology Department, Madrid, Spain
    Mov Disord 20:1343-5. 2005
    ..Gait and speech dysfunctions were distributed similarly in both countries. We found action tremor to be the most frequent PMD in both countries...
  49. ncbi The SCOPA-Motor Scale for assessment of Parkinson's disease is a consistent and valid measure
    Pablo Martinez-Martin
    National Center for Epidemiology, Carlos III Institute of Public Health, C Sinesio Delgado, 6, 28029 Madrid, Spain
    J Clin Epidemiol 58:674-9. 2005
    ..The SCOPA-Motor Scale (S-MS) for assessment of Parkinson's disease (PD), contains 21 items in three domains: Motor examination, Disability, and Complications. Our objective was to validate the S-MS Spanish version...